Boston Scientific Is a Broken Compounder, and Everyone's Pretending the Break Is Temporary

# Boston Scientific Is a Broken Compounder, and Everyone's Pretending the Break Is Temporary

Let's get the easy part out of the way: Boston Scientific just printed a quarter that would make most of Wall Street weep with envy. Revenue of $5.44 billion, up 7.5% year over year. Gross margin of 70.7%, up 305 basis points. Operating income nearly doubling. On paper, this is a machine running hot.

Then management looked the room in the eye and cut guidance twice in a single session. Full-year organic revenue growth dropped to 5%–6%. Adjusted EPS guided to $3.28–$3.32. They did this on top of an April reset that had already trimmed expectations. Two separate hits, blurred into one story, and the market has been slow to untangle them.

Here's the part nobody wants to sit with: the business is fine. The franchise is not.

Boston Scientific trades near $44, down roughly 55% from its peak, at a forward multiple around 13x that would have been unthinkable a couple of years ago. Five-year average sits near 26x. Value investors are salivating. Short sellers are sharpening knives. Both are probably right, and both are probably missing the point.

The problem isn't the numbers. It's the two franchises the market decided don't matter.

WATCHMAN, the left atrial appendage closure device that was once the crown jewel of the cardiology story, saw U.S. growth collapse to roughly 3%. Stand-alone procedures fell in the low teens. Management blamed nine months of new clinical evidence rerouting referral patterns and a rise in "concomitant" procedures now making up about a third of U.S. cases. The translation is simple: doctors stopped doing WATCHMAN alone, and the market believed them. The guidance assumes no recovery in 2027. That's not a dip. That's a floor with no bounce.

Electrophysiology is worse, because it's structural. PFA technology now represents about 80% of the U.S. atrial fibrillation market. Boston Scientific is losing share faster than the total is growing, and FARAPULSE alone holds an estimated 70% of that PFA business. The company can grow revenue off a shrinking competitive base and still come up short. That's the kind of story that doesn't fix itself on a cost program.

Now, for the record, the core is not collapsing. Interventional Cardiology grew 15% organic. Endoscopy grew 7%. Roughly three-quarters of revenue still expands at about 6%. The balance sheet carries $12.6 billion in debt, but free cash flow is positive, margins are expanding, and the CEO bought $9 million of stock in August. Insiders don't spend $9 million on shares they think are going to $28.

So what's the real read?

Boston Scientific isn't broken. It's a company with two bleeding limbs and a perfectly healthy torso, and the market has decided to price it like a corpse. The valuation math is seductive: 13x forward earnings, analyst targets clustering in the mid-$70s, a $500 million cost program, insider buying, and a product pipeline — FARAWAVE Ultra, renal denervation, a leadless pacemaker — that would justify a re-rating if any of it actually lands.

But here's the part that keeps me up at night, and it's the part the bull narrative glosses over: the market doesn't pay for what a company could do in 2028. It pays for what it does in Q3, and Q3 was guided to just 3%–5% organic growth. WATCHMAN isn't coming back next quarter. EP share losses aren't stabilizing next quarter. The August cyberattack that disrupted manufacturing and shipping — most of it "delayed rather than lost," management insists — lands squarely in that window.

The technicals agree with the fundamentals story being muddier than the headlines. The stock bottomed near $42.20, its 52-week low, and has bounced weakly. It's trading below its 200-day average by nearly 30%. Relative strength index sits at a neutral 44. Volume is thin. The bounce has no conviction, and thin-volume bounces in downtrends have a habit of folding.

I'm not going to pretend there's a clean trade here. This is a coin flip dressed up as a value play.

The bulls are right that the downside is cushioned — cheap multiple, real cash flow, real insider buying, a core business that still grows. The bears are right that two decelerating franchises with no assumed recovery date will keep the ceiling low until someone proves otherwise.

My take? This is a stock you don't chase and you don't fear. You sit on the sidelines, watch the Q3 print on October 21, and let management decide which version of the story is true. If WATCHMAN FLX adoption surprises and EP stabilizes, the mid-$50s isn't crazy. If guidance gets cut a third time and the cyberattack fallout proves stickier than "delayed not lost," the low $40s becomes the new normal fast.

The market has already made up its mind that Boston Scientific is a broken compounder. Fine. Compounders break sometimes. The question is whether you want to be the one holding the pieces when they decide to glue it back together — or the one who got scared out at the bottom.

Neither of those decisions happens in this report. It happens after October 21.